Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Tivantinib |
Synonyms | |
Therapy Description |
Tivantinib (ARQ197) inhibits MET and may have antimitotic activity, potentially resulting in decreased tumor cell proliferation and reduced tumor growth (PMID: 29924867, PMID: 28246274). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tivantinib | ARQ197|ARQ 197|ARQ-197 | MET Inhibitor 59 | Tivantinib (ARQ197) inhibits MET and may have antimitotic activity, potentially resulting in decreased tumor cell proliferation and reduced tumor growth (PMID: 29924867, PMID: 28246274). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01468922 | Phase I | Tivantinib Pazopanib | Pazopanib and ARQ 197 for Advanced Solid Tumors | Completed | USA | 0 |
NCT01755767 | Phase III | Tivantinib | Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy | Completed | USA | SWE | NZL | NLD | ITA | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 1 |
NCT02150733 | Phase I | Tivantinib | Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment | Completed | USA | 0 |